SeekingAlpha · Nov 9, 2026
Certara, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-09. The following slide deck was published by Certara, Inc.
NASDAQ · CERT
Healthcare · Medical - Healthcare Information Services
$11.18
Down-$0.50 (-4.47%)
Updated Nov 20, 2026, 1:06 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CERT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
CERT closed at $11.18 after 20 trading sessions, up 10.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $11.02 | $11.355 | $11.00 | $11.18 | 1.75M |
| Nov 17, 2026 | $11.29 | $11.54 | $11.05 | $11.06 | 2.28M |
| Nov 16, 2026 | $11.35 | $11.46 | $11.15 | $11.39 | 2.84M |
| Nov 13, 2026 | $12.02 | $12.1777 | $11.545 | $11.57 | 2.67M |
| Nov 12, 2026 | $11.73 | $11.97 | $11.29 | $11.90 | 3.12M |
| Nov 11, 2026 | $12.25 | $12.38 | $11.67 | $11.73 | 3.16M |
| Nov 10, 2026 | $12.00 | $12.27 | $11.85 | $12.125 | 2.88M |
| Nov 9, 2026 | $12.06 | $12.60 | $11.98 | $12.22 | 5.84M |
| Nov 6, 2026 | $12.03 | $12.61 | $11.79 | $12.05 | 4.87M |
| Nov 5, 2026 | $11.21 | $12.25 | $10.82 | $12.18 | 3.73M |
| Nov 4, 2026 | $11.08 | $11.275 | $10.7801 | $11.09 | 2.43M |
| Nov 3, 2026 | $10.58 | $11.02 | $10.4598 | $10.87 | 1.87M |
| Nov 2, 2026 | $11.08 | $11.09 | $10.645 | $10.71 | 1.95M |
| Oct 30, 2026 | $11.07 | $11.19 | $10.645 | $11.02 | 1.95M |
| Oct 29, 2026 | $11.46 | $11.57 | $11.08 | $11.20 | 2.75M |
| Oct 28, 2026 | $10.84 | $11.73 | $10.84 | $11.48 | 2.37M |
| Oct 27, 2026 | $10.50 | $10.98 | $10.435 | $10.95 | 2.42M |
| Oct 26, 2026 | $10.20 | $10.625 | $10.0793 | $10.61 | 2.35M |
| Oct 23, 2026 | $9.95 | $10.37 | $9.835 | $10.33 | 2.06M |
| Oct 22, 2026 | $10.14 | $10.31 | $9.86 | $10.09 | 2.37M |
The latest Smart Investors Daily articles mentioning CERT.
Company
Market Activity
Research & News
CERT research
Company profile and research snapshot.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 6, 2026 | Barclays | Equal-Weight | — |
| Oct 16, 2026 | Keybanc | Overweight | — |
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Sep 30, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Nov 9, 2026
2026-11-09. The following slide deck was published by Certara, Inc.
SeekingAlpha · Nov 6, 2026
Certara, Inc. (CERT) Q3 2026 Earnings Call November 5, 2026 8:30 AM ESTCompany ParticipantsJon Resnick - CEO & DirectorFaiz Mohammed - Interim CFO,...
Benzinga · Nov 6, 2026
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $9 to $12.
Yahoo · Nov 6, 2026
How Certara’s Q3 earnings changed the conversation Certara (CERT) put fresh numbers on the table with its Q3 2026 report, giving investors new data on profitability, software momentum, and the trade off between quarterly strength and year to date losses. Sales for the quarter reached US$94.9 million compared with US$90.89 million a year earlier, while net income was US$5.59 million compared with US$1.53 million. Earnings per share for the period came in at US$0.04 on both a basic and diluted...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CERT.